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Abstract
In March 2013, diagnosis of the first reported case of human infection with a novel avian-origin 
influenza A(H7N9) virus occurred in eastern China. Most human cases have resulted in severe 
respiratory illness and, in some instances, death. Currently there are no licensed vaccines against 
H7N9 virus, which continues to cause sporadic human infections. Recombinant virus-like particles 
(VLPs) have been previously shown to be safe and effective vaccines for influenza. In this study, 
we evaluated the immunogenicity and protective efficacy of a H7N9 VLP vaccine in the ferret 
challenge model. Purified recombinant H7N9 VLPs morphologically resembled influenza virions 
and elicited high-titer serum hemagglutination inhibition (HI) and neutralizing antibodies specific 
for A/Anhui/1/2013 (H7N9) virus. H7N9 VLP-immunized ferrets subsequently challenged with 
homologous virus displayed reductions in fever, weight loss, and virus shedding compared to these 
parameters in unimmunized control ferrets. H7N9 VLP was also effective in protecting against 
lung and tracheal infection. The addition of either ISCOMATRIX or Matrix-M1 adjuvant 
improved immunogenicity and protection of the VLP vaccine against H7N9 virus. These results 
provide support for the development of a safe and effective human VLP vaccine with potent 
adjuvants against avian influenza H7N9 virus with pandemic potential.
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1. Introduction
An outbreak of human infection caused by a novel avian-origin influenza A H7N9 virus 
emerged in eastern China in the spring of 2013 [1]. In late March, the notification of three 
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human cases of H7N9 in Shanghai and Anhui, all of whom died after acute respiratory 
distress syndrome (ARDS) and multi-organ failure, raised public health concerns [1]. As of 
March 2015, the World Health Organization (WHO) had reported over 500 infections and 
over 200 deaths, mostly in China (http://www.who.int/en/). Most human infections have 
been the result of exposure to infected poultry or with environments where animals are 
housed [1,2]. Multiple reassortment events resulted in a novel H7N9 virus with six internal 
genes derived from an avian influenza A(H9N2) virus [1,3–5]. Despite the considerable 
morbidity and mortality caused by H7N9 virus, no sustained human-to-human transmission 
of this subtype has been documented. However, because humans are immunologically naïve 
to this subtype, the emergence of a transmissible H7N9 virus presents a significant public 
health concern.
While H7N9 cases have remained sporadic, routine pandemic preparedness measures, 
including vaccine development, have continued to date. However, there are currently no 
approved human vaccines for H7N9 viruses. Traditional egg-based vaccine manufacturing 
methods require time-consuming propagation and purification, taking at least 6 months to 
produce large quantities of influenza vaccine. The development of safe vaccines by 
reassortment and reverse genetics methods also requires additional evaluation for adequate 
safety [6]. Experimental vaccines have been previously developed for H7 subtype viruses; 
however H7N9 candidate vaccines have not been sufficiently evaluated in preclinical and 
clinical settings [7–10]. Recombinant virus-like particles (VLPs) are considered a promising 
egg-independent vaccine approach that has been previously shown to be a safe and effective 
vaccine against influenza [11–17]. An H7N9 VLP vaccine candidate was rapidly developed 
in early 2013 and shown to induce protective immunity against H7N9 virus in mice [10]. 
Although VLP vaccines alone are sufficiently immunogenic, the addition of adjuvants can 
improve the performance of vaccines and reduce the required dosage. One strategy to 
improve vaccine efficacy is by the addition of saponin-based adjuvants such as 
ISCOMATRIX and Matrix-M1 [18]. Saponin-based adjuvants have the ability to enhance 
both humoral and cellular immune responses, including CD8+ T-cell immunity [18,19].
Ferrets are considered to be the most suitable animal model for influenza vaccine efficacy 
studies [13,20–22]. Using this and other animal models, experimental influenza VLP 
vaccines have shown protective efficacy against potentially pandemic H5N1 and H9N2 
viruses, as well as the 2009 pandemic H1N1 virus [7,13,15,23,24,16]. In this study, 
influenza virus genes cloned into a baculovirus expression vector to produce H7N9 VLP in 
Spodoptera frugiperda (Sf9) insect cells, were evaluated for its immunogenicity and vaccine 
efficacy in the ferret challenge model. We demonstrate that the experimental H7N9 VLP 
vaccine induced pre-challenge serum neutralizing antibody titers of ≥80 which were 
associated with protection of ferrets. Influenza vaccination with H7N9 VLP vaccine also 
prevented significant virus replication in the lung and trachea of ferrets upon subsequent 
challenge. The saponin-based ISCOMATRIX and Matrix-M1 adjuvants, shown previously 
to be safe and well tolerated in humans [19], were found to enhance the immunogenicity and 
protection efficacy of H7N9 VLPs.
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2. Materials and methods
2.1. Viruses and cloning of HA, NA, and M1 genes
Influenza hemagglutinin (HA) H7 and neuraminidase (NA) N9 sequences of A/Anhui/
1/2013 (Anhui/1; H7N9) virus were obtained from the GISAID Epiflu database 
(www.gisaid.org) with accession numbers EPI439507 and EPI439509, respectively. Both 
genes were codon-optimized for high-level expression in Sf9 insect cells (ATCC, Manassas, 
VA) and synthesized biochemically (Genscript, Piscataway, NJ). The matrix (M1) sequence, 
GenBank accession no. ABI36004, was from A/Indonesia/5/2005 (H5N1) virus and was 
codon-optimized for high-level expression and synthesized (Geneart, Regensburg, 
Germany). In order to generate VLPs, full-length H7, N9 and M1 genes were cloned into 
baculovirus (rBV) pFastBac1 transfer vectors between BamHI and HindIII sites downstream 
from a polyhedrin promoter, as described elsewhere [10,15]. Recombinant rBV expressing 
H7, N9, and M1 genes were generated by using a Bac-to-Bac baculovirus expression system 
(Life Technologies, Carlsbad, CA). The titers of rBV preparations were determined by 
plaque assay in Sf9 cells and expressed as plaque forming units (pfu)/ml. For expression of 
VLPs, Sf9 cells were maintained as suspension cultures in HyQ-SFX insect serum free 
medium (HyClone, Logan, UT) at 27 ± 2 °C. Recombinant baculovirus stocks were 
prepared by infecting cells at a low multiplicity of infection (MOI) of ≤0.01 pfu per cell and 
harvested at 68–72 h post-infection.
2.2. Preparation of H7N9 VLPs
For production of H7N9 VLPs, Sf9 cells were adjusted to 2 × 106 cells/ml and co-infected at 
a MOI of 0.5 pfu per cell for 68–72 h with rBVs expressing H7, N9, and M1 genes. The 
H7N9 VLPs were harvested from Sf9 growth medium supernatant, concentrated and 
purified. Briefly, infected Sf9 cells were incubated with continuous agitation at 27 ± 2 °C 
and harvested by centrifugation at 4000 × g for 15 min. Cell culture supernatant containing 
VLP and baculovirus particles was initially concentrated and dialyzed against buffer using 
hollow fiber tangential flow filtration. Then, separation of VLP from baculovirus and other 
host contaminants was accomplished by using anion exchange followed by gel filtration 
chromatography. Purified H7N9 VLPs in PBS were filter sterilized using a 0.2 μm filter and 
stored at 2–8 °C until vaccinations.
2.3. Characterization of VLPs
VLPs were examined by SDS-PAGE using 4–12% polyacrylamide gels (Life Technologies, 
Carlsbad, CA) followed by staining with Gel-Code Blue stain (Pierce, Rockford, IL). The 
content of H7 within VLPs was quantitated by densitometry analysis of stained gels. VLPs 
were also evaluated for total protein concentration (BCA bicinchoninic acid protein assay, 
Pierce Biochemicals, Rockford, IL) and particle size by dynamic light scattering with a 
ZETASizer Nano (Malvern Instruments, PA) using standard manufacturer recommended 
methods. Western blot was done using rabbit anti H7N7 for HA (Sino Biologicals, Beijing, 
China) and mouse anti-influenza A M1 for M1 (AbD Serotec, Kidlington, UK).
For transmission electron microscopy, H7N9 VLPs were adsorbed onto freshly discharged 
400 mesh carbon parlodion-coated copper grids (Poly-Sciences, Warrington, PA). The grids 
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were rinsed with buffer containing 20 mM Tris, pH 7.4, and 120 mM KCl and negatively 
stained with 1% phosphotungstic acid, then dried by aspiration. VLPs were visualized on a 
Hitachi H-7600 transmission electron microscope (Hitachi High Technologies America, 
Schaumburg, IL) operating at 80 kV and digitally captured with a CCD camera at 1 k × 1 k 
resolution (Advanced Microscopy Techniques Corp., Danvers, MA).
The hemagglutination titer was determined by serially diluting VLPs at two-fold increments 
in 50 μl in a 96-well plate. To each VLP dilution, 50 μl of 0.75% horse red blood cell (RBC) 
working solution was added, mixtures of VLPs and RBCs were gently agitated and the plate 
was incubated at 25 °C for 30–60 min before examination recommended by the WHO [17]. 
Negative hemagglutination results appeared as dots in the center of the wells. The titer was 
calculated as the highest dilution factor that produced a positive reading. For 
hemagglutination assays, dilutions of VLPs were mixed with horse RBCs.
The neuraminidase enzymatic activity of VLPs was determined by using a fluorescence-
based NA assay (NA-Fluor, Life Technologies) with methyl umbelliferone N-acetyl 
neuraminic acid (MUNANA; Sigma, St Louis, MO) as a substrate according to 
manufacturer’s instructions.
2.4. Vaccinations and challenge
All animal experiments were performed under the guidance of the Centers for Disease 
Control and Prevention’s Institutional Animal Care and Use Committee and were conducted 
in an Association for Assessment and Accreditation of Laboratory Animal Care 
International-accredited animal facility. Adult male Fitch ferrets, 4–5 months of age (Triple 
F Farms, Sayre, PA), serologically negative by hemagglutination inhibition (HI) assay for 
currently circulating influenza viruses, were used in this study. Groups of six ferrets received 
two intramuscular (i.m.) inoculations (4–5 weeks apart) of 15 μg of total HA in the VLPs 
with and without adjuvant in a 0.5 ml volume. PBS treated ferrets served as unimmunized 
controls. The adjuvants, Matrix-M1 (Novavax, AB, Uppsala, Sweden) and 
ISCOMATRIXTM (CSL Biotherapies Inc., King of Prussia, Pennsylvania, USA; 
ISCOMATRIX is a registered trademark of ISCOTEC Ab, a CSL company) were mixed 
with antigen for 20–30 min prior to injection, as described by the manufacture. Adjuvants 
were added in a 1:1 v/v ratio giving a final concentration of 60 ISCO units (IU)/0.5 ml for 
ISCOMATRIX and 50 μg/0.5 ml for Matrix-M1 adjuvant. The vaccine dose of 15 μg and 
i.m. route of administration is consistent with current human vaccination practices [25]. 
Prior to primary vaccination, vaccine boost, and viral challenge, all ferrets were bled for 
collection of serum to assess responses to vaccination and then challenged intranasally (5 
weeks following boost) with 106 pfu of H7N9 virus in a total volume of 1 ml (500 μl per 
nostril). Following challenge, ferrets were monitored daily for changes in body weight and 
temperature, as well as clinical signs of illness. Nasal wash samples were collected at 2, 4, 6, 
and 8 days post-challenge (p.c.) and titrated in a standard plaque assay to determine viral 
titers in the upper respiratory tract. The statistical significance of differences in weight loss, 
temperature changes, and virus titers between vaccinated and PBS-control animals were 
determined by ANOVA.
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Six ferrets per group were additionally challenged with homologous virus and euthanized 
days 3 or 5 p.c. (3 per time point) for collection of nasal wash, nasal turbinates, trachea, and 
lung as previously described [26]. All samples were immediately frozen at −80 °C until use. 
Tissues were homogenized in 1 ml cold PBS and titrated by standard plaque assay in MDCK 
cells as previously described [27]. The limit of virus detection was 10 pfu.
2.5. Serological assays
All sera were initially diluted 1:10 in receptor-destroying enzyme from Vibrio cholerae 
(Denka Seiken, Tokyo, Japan). Both HI and neutralization assays were performed. The HI 
assay was performed using 0.5% turkey or 1% horse erythrocytes with 4 hemagglutination 
units (HAU) of homologous viruses using standard methods [15]. Titers of virus neutralizing 
(VN) antibody were determined essentially as described [28] and expressed as the reciprocal 
of the highest dilution of serum that neutralized 100 pfu of virus in MDCK cell cultures. The 
neutralization titers were presented as the geometric mean titers (GMT) from vaccinated or 
control ferrets.
3. Results
3.1. Characterization of H7N9 VLP vaccine
Influenza H7N9 VLPs were constructed in a rBV expression system with the sequences of 
the virus genes for HA, NA and M1 (Fig. 1A). The H7 and N9 proteins were derived from 
sequences of A/Anhui/1/2013 (Anhui/1; H7N9) virus and the conserved M1 protein, derived 
from an H5N1 virus, was previously shown to be sufficient for successful preparation of 
chimeric VLPs [10]. The presence of H7 and M1 proteins in VLPs was confirmed by SDS-
PAGE and Western blot with antibodies specific for HA and M1 (Fig. 1B). Using a universal 
NA antibody, it was previously shown that the N9 within VLPs co-migrated with HA on the 
gel [10], and the HA:NA mass ratio is 5.6:1 as determined previously by capillary gel 
electrophoresis [10]. The expressed H7 HA of the VLPs represented uncleaved HA0 
polypeptide of 62–64 kilodaltons (kDa). The M1 protein, which has been previously shown 
to be a major structural component of influenza VLP complexes [7,15], is 252 aa in length 
with the expected molecular mass of approximately 25 kDa. Functionally, the VLPs 
exhibited high titer hemagglutination activity (HAU = 2048 per 0.40 mg/ml total VLP 
protein), as titrated with horse RBCs, confirming that the incorporated HA protein retained 
its stability and binding capacity (Fig. 1C). The H7N9 VLPs also displayed NA enzymatic 
activity in a standard fluorescence-based influenza neuraminidase assay (Fig. 1C). The size 
and morphology of VLPs were further examined by negative-staining transmission electron 
microscopy (TEM) (Fig. 1D). The H7N9 VLPs were identified as largely spherical, typical 
influenza-like enveloped particles, which average approximately 164 nm in diameter with 
characteristic spikes of HA protruding from the VLP envelope.
3.2. Immunogenicity and protective efficacy of H7N9 VLPs in ferrets
In the first experiment, ferrets received two intramuscular (i.m.) vaccinations of H7N9 VLPs 
in the presence or absence of ISCOMATRIX adjuvant; control animals received PBS in 
place of vaccine. There were no adverse effects at the injection site in any of the ferrets 
following immunization. The HI and neutralization antibody responses to H7N9 virus were 
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measured among individual serum samples collected just prior to vaccine boost and virus 
challenge. As expected, no antibody responses to H7N9 were detected in the serum of 
control animals. A single 15 μg VLP vaccine dose elicited a detectable neutralizing antibody 
response in all vaccinated ferrets (geometric mean titer [GMT] = 16) (Table 1). The addition 
of ISCOMATRIX to the VLP vaccine increased neutralizing titers (≥40) (GMT = 63) to 
Anhui/1 (H7N9) virus. A vaccine boost led to substantial increases in neutralizing antibody 
titers that ranged from 80 to 160 (GMT = 113) in the unadjuvanted group and 160 to 320 
(GMT = 254) among ferrets that received VLP with ISCOMATRIX. HI antibody titers 
measured in sera of adjuvanted and non-adjuvanted ferrets followed a similar pattern to the 
neutralizing antibody response, albeit at lower titers (Table 1). All vaccinated ferrets 
displayed pre-challenge HI antibody titers of ≥80 to Anhui/1 virus; the pre-challenge HI 
titers were highest among the VLP/ISCOMATRIX-vaccinated ferrets (GMT = 142) 
compared to ferrets in the unadjuvanted group (GMT = 80). Overall, these data indicate that 
the VLP vaccine elicited high-titer serum neutralizing antibodies specific for H7N9 virus 
and the addition of ISCOMATRIX augmented the antibody response to vaccination.
We next determined the level of protection against homologous virus challenge induced by 
H7N9 VLP vaccine. Vaccine protection was measured by reduction in fever, weight loss, 
and viral shedding in ferrets following a stringent challenge dose (106 pfu) of Anhui/1 virus. 
Unimmunized control ferrets challenged with Anhui/1 virus displayed fever, weight loss and 
transient inactivity. On day 2 post-challenge (p.c.), all control ferrets exhibited an early spike 
in body temperature, ranging from 0.8 to 2.9 °C over baseline (mean maximum = 2.3 °C) 
(Table 2); elevated temperatures (>1.0 °C over baseline) were maintained for 4 days p.c. (not 
shown). VLP- and VLP/ISCOMATRIX-vaccinated animals also displayed an early (day 2 
p.c.) spike in body temperature (mean maximum = 2.0 °C and 1.3 °C, respectively), however 
body temperatures returned to baseline by day 4 p.c. and both vaccinated groups displayed 
significantly lower (p ≤0.05) temperatures compared to control ferrets. Significant 
differences in weight loss were also observed between vaccinated and control ferrets (Table 
2 and Fig. 2). Control animals exhibited 12.7% mean maximum weight loss compared with 
7.4% and 3.5% weight loss for VLP- and VLP/ISCOMATRIX-vaccinated ferrets, 
respectively.
The extent of virus replication in the upper respiratory tract was determined by titrating 
nasal wash samples collected from immune and control ferrets on alternate days post-
challenge (p.c.) In comparison to control animals, H7N9 VLP-vaccinated ferrets displayed a 
significant reduction in viral shedding on days 2, 4 and 6 p.c. (Table 2 and Fig. 3). The 
addition of ISCOMATRIX adjuvant to H7N9 VLP vaccine provided enhanced protection 
against virus shedding compared with VLP only. Viral titers measured in VLP/
ISCOMATRIX-vaccinated ferrets were significantly reduced on all days measured (2, 4 and 
6 p.c.) and these ferrets exhibited a faster rate of virus clearance compared with PBS 
controls (Fig. 3). Taken together, these data demonstrate that the VLPs, especially when 
adjuvanted, offered reductions against substantial fever, weight loss, and viral shedding 
following H7N9 virus challenge.
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3.3. The effect of H7N9 VLP vaccination on the virus replication in the ferret respiratory 
tract
In the second experiment, VLP vaccine efficacy was assessed using a second saponin-based 
adjuvant, Matrix-M1. The extent of VLP vaccine protection against H7N9 virus was 
measured as viral titers in lung and upper (nasal turbinate and trachea) respiratory tract 
tissues at the peak of virus replication. Ferrets received two i.m. vaccinations of H7N9 VLPs 
in the presence or absence of Matrix-M1 adjuvant and control animals received PBS in place 
of vaccine. Similar to the first vaccine experiment, the neutralizing antibody responses to 
H7N9 virus were measured in individual serum samples collected prior to vaccine boost and 
challenge (Table 1, experiment 2). A single immunization elicited a detectable neutralizing 
antibody response in all VLP-M1 vaccinated and five of six VLP-only vaccinated ferrets. 
Following booster vaccination, neutralizing antibody responses to H7N9 virus were 
substantially elevated in all vaccinated ferrets. The pre-challenge neutralizing antibody titers 
against Anhui/1 virus ranged from 80 to 160 (GMT = 101) in the VLP vaccinated ferrets and 
160 to 320 (GMT = 285) VLP-M1 vaccinated animals.
Vaccinated and control ferrets were similarly challenged with 106 pfu of Anhui/1 virus five 
weeks after vaccine boost. On days 3 and 5 p.c., unimmunized control animals showed high 
titers (≥4.2 mean log10 pfu/ml) of infectious virus in each of the three respiratory tract 
tissues (Fig. 4). Conversely, mean tissue titers among VLP vaccinated ferrets were lower and 
significant reductions were achieved in trachea (p < 0.05) and lung tissues (p < 0.001) days 3 
and 5 p.c. Notably, no infectious virus was recovered from lung tissues of any ferrets 
administered VLP vaccine plus M1 adjuvant. Among ferrets that received VLP vaccine only, 
no virus was detected in lungs on day 5 p.c. and the mean lung virus titers at day 3 p.c. were 
2200-fold less than unimmunized controls. Virus titers in nasal turbinates (NT) were 
significantly reduced on day 5 p.c. among ferrets inoculated VLP vaccine plus M1 adjuvant 
(Fig. 4B). VLP-M1 vaccination also resulted in a significant reduction in virus shedding 
measured on days 3 and 5 p.c. (Fig. 5). Taken together, these data suggest that VLP 
immunization also prevented significant virus replication in the ferret lung and trachea and 
the addition of M1 adjuvant enhanced the protective efficacy of the VLP vaccine.
4. Discussion
Similar to avian influenza H5N1 subtype viruses, avian H7 viruses have caused outbreaks 
and human infection in recent years and continue to pose a public health threat. The 
continuing occurrence of human H7N9 infections and the suboptimal immunogenicity of H7 
vaccines underscore the need for continued development of improved influenza vaccines 
[29–31]. Although it has been shown that a H7N3 live attenuated influenza vaccine can be 
protective against H7N9 virus due to the presence of conserved antigenic sites on the H7 HA 
[5], an H7N9-specific vaccine is needed for optimal protection. The WHO reported that a 
comparison of A(H7N9) viruses isolated from humans, poultry and environmental samples 
using HI assays shows that limited antigenic diversity exists among this group of viruses 
(http://www.who.int/en/). Thus, based on genetic and antigenic analysis of H7N9 viruses, 
the WHO has recommended that A/Anhui/1/2013-like virus be used for the development of 
influenza H7N9 vaccines for pandemic preparedness purposes. Using the ferret model, 
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regarded as the most relevant model for influenza vaccine efficacy assessments, we showed 
that an H7N9 VLP vaccine induced high levels of virus-neutralizing antibodies to Anhui/1 
virus, which were augmented by the addition of saponin-based adjuvants, ISCOMATRIX or 
Matrix-M1. H7N9 VLP vaccination was effective at significantly reducing viral shedding 
and lung viral loads associated with H7N9 virus infection.
Several experimental H7 influenza vaccines have been developed and evaluated. They 
include a live attenuated H7N7 candidate vaccine virus containing a modified HA from the 
highly pathogenic A/Netherlands/219/2003 (H7N7) virus that protected mice, ferrets, and 
monkeys from virus challenge [32]. Moreover, a live attenuated H7N3 influenza virus 
vaccine was well tolerated and immunogenic in a Phase I clinical trial in healthy adults [33]. 
Conversely, a clinical trial of an inactivated H7N7 virus vaccine in healthy young adults 
exhibited low immunogenicity despite vaccinations with two doses of up to 90 μg of HA 
[34]. Recent results from a phase 1 study in healthy adults demonstrated that an adjuvant 
(MF59) was required to achieve significant HI antibody responses to H7N9 virus [35]. 
Evaluations for in vitro correlates of immunogenicity of inactivated H5, H7 and H9 vaccines 
in humans revealed that low HA titer was associated with low immunogenicity, whereas the 
presence of particles or split virus pieces was associated with higher immunogenicity [36]. 
This suggested that correct conformation and localization of H7 within the intact virus 
particle vaccine is important for optimal immunogenicity. Another type of vaccine is the 
cell-based H7N1 split influenza virion, which was shown to confer protection in the mouse 
and ferret challenge models [37]. More recently, protection against H7N9 viruses has been 
reported using viral vector vaccines [38,39].
In the present study, recombinant VLPs were generated from structural proteins of the 
Anhui/1 H7N9 virus. The size and morphology of the H7N9 VLPs resembled influenza 
virions and confirmation of HA0 on the outer surface of VLPs along with hemagglutination 
and neuraminidase functions, suggested proper H7N9 VLP self-assembly. Although 
negative-staining TEM was not performed on the VLP/adjuvant formulations, previously 
unpublished TEM images on other VLPs in saponin-based adjuvants have shown no obvious 
interactions or changes in VLP morphology compared to VLP without adjuvant (Smith, 
personal communication). We tested the ability of adjuvanted and non-adjuvanted H7N9 
VLPs to provide protection in a stringent (106 pfu) challenge model. We used 15 μg of total 
HA in the VLPs, which represents the standard dose per virus contained in licensed 
inactivated seasonal influenza vaccines. In the first vaccine experiment, all ferrets that 
received VLP plus ISCOMATRIX adjuvant were well protected against weight loss and 
prolonged viral shedding. Ferrets vaccinated with adjuvant generally had higher levels of HI 
and neutralizing antibodies than did non-adjuvant vaccinated ferrets. Even without adjuvant, 
the VLP vaccine elicited pre-challenge HI titers of ≥40, which is generally accepted to 
represent a 50% protective titer for seasonal influenza viruses in adult populations [40]. An 
enhancing effect of ISCOMATRIX adjuvant on the immunogenicity of VLP vaccination has 
been demonstrated in mice [10] and in humans [19]. It is generally believed that 
ISCOMATRIX adjuvant possesses two main functions: efficient antigen delivery (i.e. 
promotes trafficking of vaccine particles directly into draining lymph nodes) and potent 
immune activation by inducing both Th1 and Th2 type responses [41]. As ferret specific 
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reagents become more widely available, the utility of this challenge model to investigate T-
cell functions with respect to adjuvant use will increase.
The clinical course of H7N9 virus infection in humans can result in the progression of 
severe pneumonia and ARDS [1]. Further progression of lung injury may result in 
inadequate gas exchange, lower respiration, and ultimately death. Thus, unlike seasonal 
influenza virus infection, H7N9 virus can efficiently replicate in lung tissue resulting in an 
inflammatory response and potentially decreased lung function [42]. Therefore, it was 
important to examine whether H7N9 VLP vaccine provided significant protection in the 
lung. Strikingly, only trace amounts of infectious virus were found in lung tissue of two of 
three vaccinated ferrets on day 3 p.c. and no virus was measured (above the limit of 
detection) on day 5 p.c. H7N9 VLP vaccination also prevented significant virus replication 
in the trachea tissues. Similar to the immunogenicity-enhancing effect of ISCOMATRIX, the 
Matrix-M1 adjuvant induced an enhanced neutralizing antibody response and improved VLP 
vaccine protection against H7N9. Although the precise mechanism of Matrix-M1 action has 
not been well studied, most likely this adjuvant functions similar to other saponin-based 
adjuvants by improving antigen delivery and stimulating immune responses.
Influenza VLPs are relatively easy to develop and manufacture, offering certain advantages 
over current influenza vaccine technologies [15,43]. VLP vaccine technology is particularly 
advantageous since it provides cost-effective manufacturing processes that alleviate safety 
restrictions associated with live virus vaccines. Moreover, the non-egg based manufacturing 
process could be used to help meet the demand for influenza preparedness and surge 
capacity against emerging avian influenza viruses, such as H7N9. Influenza VLPs can also 
accommodate multiple subtypes of HA in their envelopes. In a recent study, novel multi-
subtype VLPs, which co-localized H5, H7, and H9 subtypes of HA within the envelope 
protected ferrets from experimental infection challenge with three avian influenza viruses 
[7,8].
The emergence of a novel reassortant avian influenza H7N9 virus that continues to transmit 
zoonotically to humans represents a significant threat to human health [1]. The data 
presented here suggest that Anhui/1 VLPs represent a useful vaccine for H7N9 influenza 
virus. Moreover, ISCOMATRIX and Matrix-M1 adjuvants improved immunogenicity and 
protection of the VLP vaccine. Such a vaccine capable of reducing virus shedding and virus 
load in lung tissue may attenuate disease caused by H7N9 virus and may also reduce 
potential transmission of virus to susceptible hosts.
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Fig. 1. 
Recombinant baculovirus (rBV) construct and expression of A/Anhui/1/2013 (H7N9) VLPs 
in Sf9 cells. (A) Influenza HA, NA and M1 were codon-optimized for high-level expression 
in Sf9 cells and synthesized biochemically. The HA, NA, and M1 genes were combined 
within rBV in a tandem fashion so that each gene was expressed from its own expression 
cassette that included polyhedrin promoter and polyadenylation signal. (B) Expression of 
H7N9 VLPs by SDS-PAGE (left panel) and Western blot. The molecular weight (MW) of 
uncleaved HA0 was approximately 62–64 kilodalton (kDa). Western blot was done using 
rabbit anti-H7N7 and mouse anti-influenza A M1 (right panel). (C) Properties and functions 
of the H7N9 VLPs, and (D) negative staining electron microscopy of H7N9 VLPs. Bar, 100 
nm.
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Fig. 2. 
Morbidity of VLP vaccinated ferrets following Anhui/1 virus challenge. Ferrets (6 per 
group) received two intramuscular inoculations (4 weeks apart) in the presence or absence of 
ISCOMATRIX adjuvant and control animals received PBS in place of vaccine. Following 
H7N9 virus challenge ferrets were weighed daily to measure morbidity. Average weights in 
each vaccine group were measured for the duration of the study, and percent original body 
weight was calculated based on the average starting weight for each group on day 0. 
Statistical significance from PBS group was determined by analysis of area under curve 
(AUC) with ANOVA and Bonferroni post-test; p < 0.05 for VLP versus PBS, p < 0.001 for 
VLP + ISCO versus PBS group.
Liu et al. Page 14
Vaccine. Author manuscript; available in PMC 2018 February 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
H7N9 VLP vaccine efficacy following Anhui/1/virus challenge. Ferrets (6 per group) 
received two intramuscular inoculations (4 weeks apart) in the presence or absence of 
ISCOMATRIX adjuvant and control animals received PBS in place of vaccine. The nasal 
cavities of challenged ferrets were washed with 1 ml PBS every other day beginning on day 
2 p.c. and virus titers were determined. Statistical significances were determined by two-way 
ANOVA. ***Indicates statistical significance (p < 0.001) in viral titers between PBS and 
VLP-vaccinated groups for each day post-challenge.
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Fig. 4. 
H7N9 VLP vaccine protection against lung replication. Ferrets (6 per group) received two 
intramuscular inoculations (5 weeks apart) in the presence or absence of Matrix-M1 
adjuvant and control animals received PBS in place of vaccine. Animals were challenged i.n. 
with 106 pfu of influenza A/Anhui/1/2013 (H7N9) virus. Viral titers of influenza virus in 
tissues on day 3 (A), and day 5 post-challenge (B) were determined by a standard plaque 
assay. Infectious virus was detectable in lung tissues of two of three vaccinated ferrets on 
day 3. The data shown are mean values plus standard deviations (error bars) for 3 ferrets per 
group for each time period. The differences in viral titers between groups were analyzed by 
two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 5. 
H7N9 VLP vaccine protection against virus shedding. Ferrets (6 per group) received two 
intramuscular inoculations (5 weeks apart) in the presence or absence of Matrix-M1 
adjuvant and control animals received PBS in place of vaccine. Animals were challenged i.n. 
with 106 pfu of Anhui/1 virus. Nasal washes were collected prior to euthanasia (3 ferrets/
time point) and titrated in a standard plaque assay. The differences in viral titers between 
groups were analyzed by two-way ANOVA. *p < 0.05, ***p < 0.001.
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Table 1
Geometric mean of neutralizing (neut) and hemagglutination inhibition (HI) serum antibody titers following 
H7N9 VLP inoculation in ferrets.a
Vaccine group Neut titerb HI titerb
Pre-boost Pre-challenge Pre-boost Pre-challenge
Experiment 1
VLP 16 (10–20) 113 (80–160) 9 (5–10) 80 (80)
VLP + ISCOMATRIX 63 (40–80) 254 (160–320) 35 (20–40) 142 (80–160)
PBS <10 <10 <10 <10
Experiment 2
VLP 20 (10–20) 101 (80–160) 7 (5–10) 63 (40–80)
VLP + M1 50 (40–80) 285 (160–320) 25 (20–40) 202 (160–320)
PBS <10 <10 <10 <10
a
Ferrets were vaccinated i.m. two times with the 15 μg of H7N9 VLP.
bSamples were tested for HI and neutralization antibody activity against A/Anhui/1/2013 virus. Geometric mean titers (with range in parentheses) 
are shown as the reciprocal of the highest dilution of serum that completely inhibits HI or that neutralized 100 pfu of infectious virus (neut).
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Table 2
Clinical symptoms observed in VLP-immune ferrets challenged with H7N9 virus.
Vaccine groupa Clinical symptoms of H7N9 challenged ferrets
Mean temp increase over baseline (3C)b Mean % weight lossc Mean peak viral titerd
VLP 2.0 7.4 5.0 ± 0.18
VLP + ISCOMATRIX 1.3 3.5 4.2 ± 0.04
PBS 2.3 12.7 6.5 ± 0.11
a
Ferrets were vaccinated i.m. two times with the 15 μg of H7N9 VLP.
b
Temperature increases over ferret baseline of 38.5 ± 0.2 °C, all maximum temperatures from day 2 p.c.
c
Mean maximum weight loss percentage values shown (day 7 or 8 post-challenge) for 6 ferrets per group.
dVirus detected in nasal wash samples, mean peak titer shown as log10 pfu/ml including standard deviation. All peak titers from day 2 p.c.
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